Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drugs in Development for Influenza</title>
<author><name sortKey="Boltz, David A" sort="Boltz, David A" uniqKey="Boltz D" first="David A." last="Boltz">David A. Boltz</name>
</author>
<author><name sortKey="Aldridge, Jerry R" sort="Aldridge, Jerry R" uniqKey="Aldridge J" first="Jerry R." last="Aldridge">Jerry R. Aldridge</name>
</author>
<author><name sortKey="Webster, Robert G" sort="Webster, Robert G" uniqKey="Webster R" first="Robert G." last="Webster">Robert G. Webster</name>
</author>
<author><name sortKey="Govorkova, Elena A" sort="Govorkova, Elena A" uniqKey="Govorkova E" first="Elena A." last="Govorkova">Elena A. Govorkova</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">20614944</idno>
<idno type="pmc">5558450</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558450</idno>
<idno type="RBID">PMC:5558450</idno>
<idno type="doi">10.2165/11537960-000000000-00000</idno>
<date when="2010">2010</date>
<idno type="wicri:Area/Pmc/Corpus">000851</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000851</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Drugs in Development for Influenza</title>
<author><name sortKey="Boltz, David A" sort="Boltz, David A" uniqKey="Boltz D" first="David A." last="Boltz">David A. Boltz</name>
</author>
<author><name sortKey="Aldridge, Jerry R" sort="Aldridge, Jerry R" uniqKey="Aldridge J" first="Jerry R." last="Aldridge">Jerry R. Aldridge</name>
</author>
<author><name sortKey="Webster, Robert G" sort="Webster, Robert G" uniqKey="Webster R" first="Robert G." last="Webster">Robert G. Webster</name>
</author>
<author><name sortKey="Govorkova, Elena A" sort="Govorkova, Elena A" uniqKey="Govorkova E" first="Elena A." last="Govorkova">Elena A. Govorkova</name>
</author>
</analytic>
<series><title level="j">Drugs</title>
<idno type="ISSN">0012-6667</idno>
<idno type="eISSN">1179-1950</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">The emergence and global spread of the 2009 pandemic H1N1 influenza virus reminds us that we are limited in the strategies available to control influenza infection. Vaccines are the best option for the prophylaxis and control of a pandemic; however the lag time between virus identification and vaccine distribution exceeds six months and concerns of vaccine safety are a growing issue leading to vaccination refusal. In the short term, antiviral therapy is vital to control the spread of influenza; however, we are currently limited to four licensed anti-influenza drugs: the neuraminidase (NA) inhibitors oseltamivir and zanamivir, and M2 ion-channel inhibitors amantadine and rimantadine. The value of NA inhibitors was clearly established during the initial phases of the 2009 pandemic when vaccines were not available, i.e. stockpiles of antivirals are valuable. Unfortunately, as drug-resistant variants continue to emerge naturally and through selective pressure applied by use of antiviral drugs, the efficacy of these drugs declines. Because we cannot predict the strain of influenza virus that will cause the next epidemic or pandemic, it is important that we develop novel anti-influenza drugs with broad reactivity against all strains and subtypes and consider moving to multiple drug therapy in the future. Here we review the experimental data on investigational antiviral agents undergoing clinical trials [parenteral zanamivir and peramivir; long acting NA inhibitors (LANI), and polymerase inhibitor T-705], experimental antiviral agents that target either the virus [hemagglutinin (HA) inhibitor Cyanovirin-N and Thiazolides] or the host [fusion protein inhibitor (DAS181), Cox-2 inhibitors and PPAR agonists].</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">7600076</journal-id>
<journal-id journal-id-type="pubmed-jr-id">3453</journal-id>
<journal-id journal-id-type="nlm-ta">Drugs</journal-id>
<journal-id journal-id-type="iso-abbrev">Drugs</journal-id>
<journal-title-group><journal-title>Drugs</journal-title>
</journal-title-group>
<issn pub-type="ppub">0012-6667</issn>
<issn pub-type="epub">1179-1950</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">20614944</article-id>
<article-id pub-id-type="pmc">5558450</article-id>
<article-id pub-id-type="doi">10.2165/11537960-000000000-00000</article-id>
<article-id pub-id-type="manuscript">NIHMS746337</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Drugs in Development for Influenza</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Boltz</surname>
<given-names>David A.</given-names>
</name>
<xref rid="FN2" ref-type="author-notes">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Aldridge</surname>
<given-names>Jerry R.</given-names>
<suffix>Jr.</suffix>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Webster</surname>
<given-names>Robert G.</given-names>
</name>
</contrib>
<contrib contrib-type="author"><name><surname>Govorkova</surname>
<given-names>Elena A.</given-names>
</name>
</contrib>
<aff id="A1">Division of Virology, Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA</aff>
</contrib-group>
<author-notes><corresp id="FN1">Correspondence should be addressed to: David A. Boltz, Ph.D., Microbiology and Molecular Biology Division, IIT Research Institute, 10 West 35th Street, Chicago, IL 60616, Phone: 312-567-4918; Fax: 312-567-4852, <email>dboltz@iitri.org</email>
</corresp>
<fn id="FN2" fn-type="present-address"><label>1</label>
<p>Present address: Microbiology and Molecular Biology Division, IIT Research Institute, Chicago, Illinois, USA</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted"><day>23</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub"><day>30</day>
<month>7</month>
<year>2010</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>16</day>
<month>8</month>
<year>2017</year>
</pub-date>
<volume>70</volume>
<issue>11</issue>
<fpage>1349</fpage>
<lpage>1362</lpage>
<pmc-comment>elocation-id from pubmed: 10.2165/11537960-000000000-00000</pmc-comment>
<abstract><p id="P1">The emergence and global spread of the 2009 pandemic H1N1 influenza virus reminds us that we are limited in the strategies available to control influenza infection. Vaccines are the best option for the prophylaxis and control of a pandemic; however the lag time between virus identification and vaccine distribution exceeds six months and concerns of vaccine safety are a growing issue leading to vaccination refusal. In the short term, antiviral therapy is vital to control the spread of influenza; however, we are currently limited to four licensed anti-influenza drugs: the neuraminidase (NA) inhibitors oseltamivir and zanamivir, and M2 ion-channel inhibitors amantadine and rimantadine. The value of NA inhibitors was clearly established during the initial phases of the 2009 pandemic when vaccines were not available, i.e. stockpiles of antivirals are valuable. Unfortunately, as drug-resistant variants continue to emerge naturally and through selective pressure applied by use of antiviral drugs, the efficacy of these drugs declines. Because we cannot predict the strain of influenza virus that will cause the next epidemic or pandemic, it is important that we develop novel anti-influenza drugs with broad reactivity against all strains and subtypes and consider moving to multiple drug therapy in the future. Here we review the experimental data on investigational antiviral agents undergoing clinical trials [parenteral zanamivir and peramivir; long acting NA inhibitors (LANI), and polymerase inhibitor T-705], experimental antiviral agents that target either the virus [hemagglutinin (HA) inhibitor Cyanovirin-N and Thiazolides] or the host [fusion protein inhibitor (DAS181), Cox-2 inhibitors and PPAR agonists].</p>
</abstract>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000851 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000851 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= Pmc |étape= Corpus |type= RBID |clé= |texte= }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |